Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia.
AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024 AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy.
AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024 AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Earnings Scheduled For March 14, 2024 Companies Reporting Before The Bell • Pharming (
NASDAQ:PHAR ) is projected to report earnings for its fourth quarter.
Chart Of The Day: Autolus Therapeutics - Effective Cancer Treatments Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer.
